TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12014813
Drug: Treatment Reinforcement
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Reinforcement Plan (TRP) - rewarded up to $15 per week for task completion
Study: 12014813
Drug: Treatment Reinforcement
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Reinforcement Plan (TRP)
Study: 12014813
Drug: Tasks related
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tasks related to therapy attendance
Study: 10408073
Drug: Estradiol patch
Normalized name: Estradiol Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol patch 0.05 mg daily for 3 weeks (Group 1)
Study: 10408073
Drug: No hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No hormone replacement (Group 2)
Study: 394794
Drug: Flupenthixol decanoate
Normalized name: flupenthixol decanoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupenthixol decanoate injections
Study: 25259426
Drug: Topical ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketorolac (n=46)
Study: 22407900
Drug: Dong-Kook Montelukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dong-Kook Montelukast Sodium Chewable Tablet 5 mg
Study: 22407900
Drug: Singulair Chewable
Normalized name: Singulair Chewable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Singulair Chewable Tablet 5 mg
Study: 21194608
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (generic risperidone tablet)
Study: 21194608
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (branded risperidone tablet)
Study: 17662757
Drug: Self-help book
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-help book with seven weekly phone calls
Study: 29563636
Drug: nintedanib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: nintedanib (200 mg bid)
Study: 29563636
Drug: sorafenib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib (400 mg bid)
Study: 21158329
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g intravenous paracetamol
Study: 21158329
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g intravenous paracetamol
Study: 14581254
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR 300 mg with moderate intensity counseling
Study: 14581254
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR 150 mg with moderate intensity counseling
Study: 14581254
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR 300 mg
Study: 14581254
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR 150 mg
Study: 11002229
Drug: Conformal external
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conformal external beam radiation therapy
Study: 8971287
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate 200 mg
Study: 8971287
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate 400 mg
Study: 8971287
Drug: Ranitidine hydrochloride
Normalized name: Ranitidine Hydrochloride
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine hydrochloride 150 mg
Study: 8971287
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (all doses)
Study: 1593689
Drug: site release
Normalized name: SOLO SITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: site release vaginal pH buffer cream
Study: 27267710
Drug: Probiotic Visbiome
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic Visbiome at 900 billion bacteria daily
Study: 10443602
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three anesthetic agents
Study: 1978862
Drug: H2-receptor antagonist
Normalized name: H2-receptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-receptor antagonist
Study: 1978862
Drug: H1-receptor antagonist,
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1-receptor antagonist, local decongestants, and antiseptic gargles
Study: 31768803
Drug: Valsartan plus
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan plus activated vitamin D (calcitriol) 0.5 μg/day
Study: 30700351
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B combined with autologous serum injection
Study: 26179651
Drug: Therapist delivered
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist delivered cognitive behavioural therapy (TCBT) plus treatment as usual (TAU)
Study: 26179651
Drug: Web-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based cognitive behavioural therapy (WBCBT) plus treatment as usual (TAU)
Study: 16968502
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg q.a.m.
Study: 2860990
Drug: Labetalol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (100 mg twice a day, increased to a maximum of 400 mg twice a day)
Study: 24225010
Drug: Spinal manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulative therapy (SMT) with home exercise (HE)
Study: 21178182
Drug: Initial implanting
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial implanting (I-implant)
Study: 21178182
Drug: Terminal implanting
Normalized name: Terminator
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terminal implanting (T-implant)
Study: 21178182
Drug: Ractopamine hydrochloride
Normalized name: ractopamine hydrochloride
DrugBank: Ractopamine (DB11541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ractopamine hydrochloride (RAC, 200 mg/(animal/d))
Study: 21178182
Drug: I-implant
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-implant
Study: 21178182
Drug: T-implant
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-implant
Study: 21178182
Drug: TRT1 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRT1 and TRT2 (1 implant)
Study: 11123733
Drug: Ketoprofen (0.3-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (0.3-3 mg x kg(-1))
Study: 11214557
Drug: Amoxicillin-clavulanate (A-C)
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate (A-C) for 10 days
Study: 31764984
Drug: High dialysate
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dialysate Mg (2.0 mEq/L)
Study: 31764984
Drug: Standard dialysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dialysate Mg (1.0 mEq/L)
Study: 11259239
Drug: Prednisolone oral
Normalized name: prednisolone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone oral solution
Study: 11259239
Drug: Crushed prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crushed prednisolone tablets
Study: 8294084
Drug: Yohimbine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (2 mg tid)
Study: 31732448
Drug: Sufentanil Sublingual
Normalized name: SUFentanil Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil Sublingual Tablet 30 mcg
Study: 28028373
Drug: Nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous oxide inhalation
Study: 28028373
Drug: Pure oxygen
Normalized name: Pure oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pure oxygen inhalation (Control)
Study: 24328992
Drug: CoreControl® (CC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoreControl® (CC)
Study: 22764846
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc (220 mg twice daily, equivalent to 50 mg elemental zinc twice daily)
Study: 18757665
Drug: Tibolone 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 1.25 mg per day
Study: 15844683
Drug: Exposure group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure group treatment (n = 33)
Study: 6860532
Drug: Metolazone 2.5
Normalized name: metolazone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metolazone 2.5 mg + Spironolactone 50 mg
Study: 6860532
Drug: Metolazone 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metolazone 0.625 mg + Spironolactone 50 mg
Study: 6860532
Drug: Metolazone 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metolazone 1.25 mg + Spironolactone 50 mg
Study: 6860532
Drug: Metolazone 2.5
Normalized name: metolazone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metolazone 2.5 mg alone
Study: 25933490
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil group (FO) - 3 g/d of fish oil ω‐3 fatty acids (10 capsules)
Study: 25933490
Drug: Extra virgin
Normalized name: Jarrow Formulas Extra Virgin Coconut Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra virgin olive oil group (OO) - 10 mL/d of extra virgin olive oil at lunch and dinner
Study: 25933490
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil and extra virgin olive oil group (FOO) - 3 g/d of fish oil ω‐3 fatty acids and 10 mL/d of extra virgin olive oil
Study: 19321022
Drug: Psychotropic medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic medications (mean number prescribed: 2.3)
Study: 12031825
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g n-3 PUFA for 14 days
Study: 12031825
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ASA (intravenous)
Study: 12031825
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA and ASA combination
Study: 10435398
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose isradipine (0.21 mg/kg orally)
Study: 10435398
Drug: Low-dose d-methamphetamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose d-methamphetamine (0.21 mg/kg orally)
Study: 10435398
Drug: High-dose d-methamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose d-methamphetamine (0.42 mg/kg orally)
Study: 371034
Drug: Antacid (Maalox)
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antacid (Maalox)
Study: 22176867
Drug: Vinflunine (VFL)
DrugBank: Vinflunine (DB11641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinflunine (VFL) therapy
Study: 20007944
Drug: Prandial insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prandial insulin aspart (IAsp) administered immediately before each meal
Study: 20007944
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin administered 30 min before each meal
Study: 17612657
Drug: Intracoronary saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary saline solution
Study: 17612657
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of adenosine (12 microg/bolus) and sodium nitroprusside (50 microg/bolus)
Study: 7890239
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg ALA
Study: 7890239
Drug: 60 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/kg ALA
Study: 7890239
Drug: Red laser
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red laser light (628 nm) treatment after ALA administration
Study: 1835398
Drug: Clodronate (1.6g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (1.6g orally daily for 18 months)
Study: 6119766
Drug: Pirenzepine 50
Normalized name: pirenzepine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 50 mg twice a day
Study: 6119766
Drug: L-hyoscyamine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-hyoscyamine 0.6 mg twice a day
Study: 27600941
Drug: Social Recovery
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social Recovery Cognitive Behavioural Therapy (SRCBT)
Study: 27600941
Drug: Both SRCBT
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both SRCBT and Treatment as usual
Study: 24359938
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen (initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 hours)
Study: 24359938
Drug: Oral paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paracetamol (15 mg/kg every 6 hours for 3 days)
Study: 21292439
Drug: Voice therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice therapy after BTX‐A injection
Study: 21292439
Drug: Sham voice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham voice therapy after BTX‐A injection
Study: 16382596
Drug: Adper Prompt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adper Prompt L-Pop (3M ESPE)
Study: 2215986
Drug: Halothane (0.8%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halothane (0.8% end-tidal) with atracurium (0.35 mg/kg)
Study: 2215986
Drug: Isoflurane (1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflurane (1% end-tidal) with atracurium (0.35 mg/kg)
Study: 626731
Drug: Pulsed oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsed oxytocin infusion (infused for one minute every ten minutes using a modified Cardiff Infusion System Mark III)
Study: 28973362
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by allo‐HSCT (HSCT group)
Study: 28973362
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (chemotherapy group)
Study: 28973362
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy (adult regimen)
Study: 23106093
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (2 hours of structured exercise weekly for 6 months)
Study: 23106093
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy (2 hours weekly for 6 months)
Study: 18844760
Drug: Antihypertensive drug
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drug treatment (perindopril, amlodipine, or labetalol)
Study: 16140433
Drug: M01ZH09 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: M01ZH09 vaccine at 5 x 10(9) CFU
Study: 16140433
Drug: M01ZH09 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: M01ZH09 vaccine at 5 x 10(8) CFU
Study: 16140433
Drug: M01ZH09 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: M01ZH09 vaccine at 5 x 10(7) CFU
Study: 13680163
Drug: Megestrol (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Megestrol (total dose 320 mg)
Study: 13680163
Drug: Hydrocortisone (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (total dose 30 mg)
Study: 8775253
Drug: Depot goserelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot goserelin acetate, 3.6 mg, subcutaneously at 4-weekly intervals
Study: 8775253
Drug: Danazol, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol, 600 mg/day
Study: 1486391
Drug: Intravenous epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous epirubicin 90 mg/m2 every 28 days
Study: 29893144
Drug: Glucose-dependent therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-dependent therapies (Strategy A)
Study: 29893144
Drug: Glucose-independent therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-independent therapies (Strategy B)
Study: 25956287
Drug: Coumarin anticoagulants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coumarin anticoagulants
Study: 21266513
Drug: Accelerated vaccination
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated vaccination schedule (10 μg HBvaxPRO, 0-1-3 week schedule)
Study: 21266513
Drug: Standard vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard vaccination schedule (10 μg HBvaxPRO, 0-4-24 week schedule)
Study: 16825691
Drug: Drink B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drink B (CPP-enriched preparation, 1.7 g CPP, 400 mg Ca as calcium lactate)
Study: 16825691
Drug: Drink C
Normalized name: Boost Energy Drink Chocolate Raspberry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drink C (CPP-enriched preparation, 1.7 g CPP, 400 mg Ca as calcium lactate)
Study: 16825691
Drug: Drink A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drink A (calcium lactate drink, 400 mg Ca as lactate)
Study: 7845645
Drug: Indomethacin suspension
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin suspension
Study: 29304325
Drug: L-PRF-plus-HA
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-PRF-plus-HA
Study: 28070894
Drug: TAS-102 tablets
Normalized name: Ta
DrugBank: TAS-102 (DB08937)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-102 tablets (60 mg; 3 × 20-mg tablets)
Study: 28070894
Drug: TAS-102 oral
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-102 oral solution (60 mg)
Study: 25824212
Drug: Benznidazole (BNZ)
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole (BNZ) at 2.5 mg/kg of body weight/12 h for 60 days
Study: 20981000
Drug: MK-0249 50
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0249 50 mg
Study: 20981000
Drug: MK-0249 10
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0249 10 mg
Study: 15845499
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of tetravalent polysaccharide vaccine for children >/=24 months old
Study: 15845499
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of tetravalent polysaccharide vaccine for children </=18 months old
Study: 11918735
Drug: 35 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mmol/L lactate dialysate
Study: 10342622
Drug: Intra-articular Sm-153
Normalized name: SM-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular Sm-153 PHYP combined with 40 mg triamcinolone hexacetonide
Study: 10342622
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg intra-articular triamcinolone hexacetonide alone
Study: 9196767
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 500 mg artemisinin with a single 500 mg oral dose of mefloquine (AM)
Study: 9196767
Drug: Mefloquine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine therapy alone (M)
Study: 24206527
Drug: Laropiprant 40mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laropiprant 40mg, clopidogrel 75mg, and aspirin 80mg (Study 1) or 81mg (Study 2) once daily for 7 days
Study: 24206527
Drug: Placebo, clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, clopidogrel 75mg, and aspirin 80mg (Study 1) or 81mg (Study 2) once daily for 7 days
Study: 20889603
Drug: Symptom diary
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom diary group (daily use for 14 days)
Study: 18552684
Drug: Aerosol antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol antibiotic (AA)
Study: 15876307
Drug: Prednisolone (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (oral glucocorticoid), 1 dose per day for 2 weeks
Study: 10087548
Drug: CapSure Z
Normalized name: Z-160
DrugBank: Z-160 (DB12743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CapSure Z leads (1.2 mm2 surface area; steroid-eluting)
Study: 10087548
Drug: CapSure SP
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CapSure SP leads (5.8 mm2 surface area; steroid-eluting)
Study: 10087548
Drug: CapSure leads
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: CapSure leads (8 mm2 surface area; steroid-eluting)
Study: 10087548
Drug: Target Tip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target Tip leads (8 mm2 surface area; no steroid elution)
Study: 7723402
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of recombinant human granulocyte‐macrophage colony‐stimulating factor (rhGM‐CSF) 5 micrograms/kg/day
Study: 7723402
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of rhGM‐CSF administered subcutaneously every 24 h
Study: 8225680
Drug: Phentermine HCl
Normalized name: phentermine HCl
DrugBank: Phentermine (DB00191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phentermine HCl capsules (Minobese Forte)
Study: 8225680
Drug: Phentermine base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentermine base capsules (Duromine)
Study: 31951263
Drug: Early intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intervention group (n = 80) receiving one-on-one physical therapy 8 times over 6 weeks and daily home exercises with wearable sensors